Skip to main content
SpringerLink
Log in

Requiring Buprenorphine Waivers for Psychiatry Residents

  • Feature: Perspectives
  • Published:
Academic Psychiatry Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.pdf. Accessed 22 Aug 2018.

  2. Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics 2018.

  3. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.

    Article  PubMed  Google Scholar 

  4. Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0094-5.

  5. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–45.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Samet JH, Botticelli M, Bharel M. Methadone in primary care—one small step for congress, one giant leap for addiction treatment. N Engl J Med. 2018;379:7–8.

    Article  PubMed  Google Scholar 

  8. Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561–83.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2018;0:1–5.

    Google Scholar 

  10. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358–64.

    Article  PubMed  CAS  Google Scholar 

  11. Substance Abuse and Mental Health Services Administration. Qualify for a physician waiver. https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver. Accessed 9/10/18.

  12. Providers Clinical Support System. MAT Waiver Training https://pcssnow.org/education-training/mat-training/. Accessed 9/10/18.

  13. American Society of Addiction Medicine. Waiver qualifying training. https://www.asam.org/education/live-online-cme/waiver-training. Accessed 9/10/18.

  14. American Psychiatric Association. Buprenorphine prescriber training. https://www.psychiatry.org/psychiatrists/education/signature-initiatives/buprenorphine-prescriber-training. Accessed 9/10/18.

  15. Suzuki J, Connery HS, Ellison TV, Renner JA. Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict. 2014;23(6):618–22.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Suzuki J, Ellison TV, Connery HS, Surber C, Renner JA. Training in buprenorphine and office-based opioid treatment: a survey of psychiatry residency training programs. Acad Psychiatry. 2016;40(3):498–502.

    Article  PubMed  Google Scholar 

  17. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–6.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Accreditation Council for Graduate Medical Education: ACGME program requirements for graduate medical education in psychiatry. Revised common program requirements effective July 1, 2017. https://www.acgme.org/Portals/0/PFAssets/ProgramRequirements/400_psychiatry_2017-07-01.pdf?ver=2017-05-25-083803-023. Accessed 9/10/18.

  19. Schwartz AC, Frank A, Welsh JW, Blankenship K, DeJong SM. Addictions training in general psychiatry training programs: current gaps and barriers. Acad Psychiatry. 2018;42(5):642–7.

    Article  PubMed  Google Scholar 

  20. Grella CE, Karno MP, Warda ES, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K, Stoller K, et al. Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. Addiction. 2013;108(11):1942–51.

    Article  PubMed  Google Scholar 

  22. Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder—and its treatment. JAMA. 2014;311(14):1393–4.

    Article  PubMed  CAS  Google Scholar 

  23. Migliore CK. The box. Ann Intern Med. 2018;169(1):58.

    Article  PubMed  Google Scholar 

  24. National Resident Matching Program. Results and data: 2018 main residency match. National Resident Matching Program. Washington DC, 2018.

  25. Sharma TR, Kablinger AS. Training general psychiatry residents to prescribe buprenorphine in treatment of patients with opioid dependence. J Grad Med Educ. 2012;4(3):391.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tesema L, Marshall J, Hathaway R, Pham C, Clarke C, Bergeron G, et al. Training in office-based opioid treatment with buprenorphine in US residency programs: a national survey of residency program directors. Subst Abus. 2018:1–7. https://doi.org/10.1080/08897077.2018.1449047.

Download references

Acknowledgments

The authors thank Dr. Anna Lembke, Associate Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine, for insightful comments and suggestions during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Stanford University School of Medicine, Palo Alto, CA, USA

    Nathaniel P. Morris & Brandon S. Bentzley

Authors
  1. Nathaniel P. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandon S. Bentzley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathaniel P. Morris.

Ethics declarations

The authors did not submit this article to an institutional review board given this work is a commentary article.

Disclosures

On behalf of all authors, the corresponding author states there are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morris, N.P., Bentzley, B.S. Requiring Buprenorphine Waivers for Psychiatry Residents. Acad Psychiatry 43, 131–134 (2019). https://doi.org/10.1007/s40596-018-1005-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40596-018-1005-4

Keywords

Search

Navigation